Which Factors Will Push The Eosinophilic Granulomatosis With Polyangiitis Treatment Market To Achieve $2.04 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Be Worth By 2029?
The market size for treatment of eosinophilic granulomatosis with polyangiitis has seen substantial growth over the past few years. The market, which was valued at $1.28 billion in 2024, is projected to rise to $1.41 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. The historical growth rate can be tied to factors like the escalating occurrences of Churg Strauss syndrome, the increased demand for viable treatment alternatives, the rise in research and development ventures, an aging population, and heightened patient awareness.
Robust expansion is anticipated in the eosinophilic granulomatosis with polyangiitis treatment market in the coming years, projected to reach a worth of $2.04 billion by 2029 while experiencing a compound annual growth rate (CAGR) of 9.7%. The impetus for this predicted growth within the forecast period is due to factors such as a greater emphasis on biologics and targeted therapies, an uptick in clinical trial activity, increased patient advocacy initiatives, a rise in precision medicine and personalized treatments, and a growing instance of asthma within the older demographic. Predominant trends within this period include the progression of technology, therapeutic agents and biologics advancements, personalized medicine strategies, partnerships between pharmaceutical industries and healthcare providers, and the creation of improved diagnostic techniques.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23392&type=smp
Which Key Factors Are Fueling Growth In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
The increase in asthma cases among the elderly is anticipated to drive the growth of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in the future. Asthma is a respiratory condition that causes a difficulty in breathing due to the swelling and narrowing of lung airways. The prevalence of asthma is growing in the aging population as a result of declining lung function, loss of elasticity in the lungs, and the weakening of airway muscles, which contributes to difficulty in breathing. This further exposes elder adults to inflammation and various respiratory issues. The surge in asthma cases among the aged leads to an increase in diagnoses for associated conditions like eosinophilic granulomatosis with polyangiitis, a condition often starting with asthma, amplifying the demand for its treatment. The Global Initiative for Asthma, a US-based medical organization, projected in 2024 that asthma is a widespread, persistent, non-transmissible disease affecting more than 260 million individuals worldwide and causing more than 450,000 deaths each year. Therefore, the increasing incidence of asthma among the elderly population is fueling the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market.
Which Segmentation Factors Are Critical In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Analysis?
The eosinophilic granulomatosis with polyangiitis treatmentmarket covered in this report is segmented –
1) By Drug Class: Steroids; Immunosuppressant; Biologics; Immune Globulins
2) By Route Of Administration: Oral; Intravenous; Intramuscular
3) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Drug Stores; Retail Pharmacies
4) By End User: Hospitals; Clinics; Home Healthcare
Subsegments:
1) By Steroids: Glucocorticoids; Mineralocorticoids
2) By Immunosuppressants: Calcineurin Inhibitors; Antimetabolites; Alkylating Agents
3) By Biologics: Interleukin Inhibitors; Monoclonal Antibodies; TNF-alpha Inhibitors
4) By Immune Globulins: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG)
What New Opportunities Are Emerging From Trends In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
Significant firms in the eosinophilic granulomatosis with polyangiitis (EGPA) therapy market are undertaking clinical studies to evaluate the security and efficacy of new and current treatments. These studies are aimed at improving treatment choices, gaining regulatory approvals, and enhancing patient care. Specifically, in September 2024, the UK-based pharmaceutical and biotechnology firm, AstraZeneca conveyed optimistic results from the MANDARA Phase III examination. This study confirmed that Fasenra (benralizumab) is successful in initiating remission in eosinophilic granulomatosis with polyangiitis patients. Additionally, it was revealed that benralizumab produced remission rates equivalent to mepolizumab and reduced the reliance on oral glucocorticoids. This development is a crucial progression towards more specific and steroid-conserving treatment strategies for eosinophilic granulomatosis with polyangiitis.
Which Players Are Shaping The Competitive Landscape Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Alkem Laboratories, NS Pharma.
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=23392&type=smp
Browse Through More Reports Similar to the Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market 2025, By The Business Research Company
Sewage Treatment Facilities Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/sewage-treatment-facilities-global-market-report
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025
Wastewater Treatment Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
